Drug General Information
Drug ID	D08OVG
Former ID	DIB016122
Drug Name	CKD-516
Synonyms	S-516; Tubulin polymerization inhibitor (iv, solid cancer), Chong Kun Dang
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[523842]
Company	Chong Kun Dang Pharmaceutical Corp
Structure		Download 2D MOL 3D MOL
Formula	C26H29ClN6O5S
Canonical SMILES	c1(nc(cs1)c1cc(c(C(=O)c2cc(c(c(c2)OC)OC)OC)cc1)n1ncnc1)<br />NC(=O)[C@@H](N)C(C)C.Cl
PubChem Compound ID	46929961
Target and Pathway
Target(s)	Tubulin beta	Target Info	Inhibitor	[532537]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 523842	ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health.
Ref 532537	CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.